GENEWIZ Acquires Beckman Coulter's Genomic Services Business

December 21, 2015
GENEWIZ Acquires Beckman Coulter's Genomic Services Business
Source: AlienForce/Fotolia

GENEWIZ said today it will acquire the genomic services (GS) business of Beckman Coulter for an undisclosed price.

Headquartered in Danvers, MA, Beckman Colter’s GS business provide sequencing services with bioinformatics solutions for healthcare businesses as well as academic institutions and government agencies worldwide.

GENEWIZ said GS's Sanger sequencing, next-generation sequencing, bioinformatics, and CLIA/clinical services will complement its existing genomics services. Those services include Sanger DNA sequencing, gene synthesis, next-generation sequencing, molecular biology, bioinformatics, and GLP/CLIA regulatory services. The company also maintains outsourcing partnerships with pharmaceutical, clinical, biotechnology, academic, and government institutions.

GENEWIZ reasons that with an international presence in the U.S. and a Pan-European presence centered in the U.K., GS presents an immediate opportunity to strengthen its global access and value to customers through a stronger network of global labs and office locations in the U.S., U.K., China, and Japan.

Headquartered in South Plainfield, NJ, GENEWIZ has additional lab locations in the U.S. in the Boston, Washington D.C., Research Triangle Park, San Diego, Los Angeles, San Francisco, and Seattle regions. In China, GENEWIZ has a regional headquarters in Suzhou with an additional laboratory facility in Beijing. Other international locations include London and Tokyo.

“The genomic services business of Beckman Coulter is an ideal fit with GENEWIZ's global strategy and expansion plans,” Steve Sun, Ph.D., GENEWIZ chairman and CEO, said in a statement. “We look forward to working with the talented GS team to best serve our customers, and be an instrumental part of the future growth of GENEWIZ."

×

Oops! Please type your email in the following format: [email protected]

You’re all set!
Thank you for subscribing to
Clinical OMICs Weekly
.